This is the authors' abstract. We don't add key points for this paper.
(See the Major Article by Erikstrup et al on pages 249–53.) Coronavirus disease 2019 (COVID-19) is an acute respiratory tract infection responsible for over 20 million diagnosed cases and 750 thousand deaths globally as of August 14, 2020 [1]. During the early stages of the epidemic few clinically ill people were tested for active infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the infectious cause of COVID-19. Furthermore, a large percentage of people infected with SARS-CoV-2 present either no symptoms or relatively mild disease [2, 3]. These facts make it difficult to estimate infection rates and prevalence as the epidemic evolves globally. This information is important for calculating absolute risks of COVID-19 disease and deaths, predicting the spread of the virus in communities based on levels of presumptive immunity following infection, and development and monitoring the impact of implementation and relaxation of epidemic mitigation policies. Measures to mitigate transmission have substantially slowed the course of the epidemic in most countries but also slowed the development of herd immunity. As infection rates increase, many questions remain as to the level of protection presumed by herd immunity, particularly in asymptomatic and mildly infected individuals who develop less robust immune responses and may be at higher risk for reinfection [4–6]. The majority of individuals mount an effective immune response during infection, leading to viral eradication and the production of specific antibodies against SARS-CoV-2 that are detectable 10–21 days after infection [7, 8]. Although the early focus of diagnostic test development and scale-up was on molecular assays for viral RNA in oral-pharyngeal swab samples, more recently there have been many advances in development and applications of serological assays in order to conduct serosurveys to understand the level of antibody (Ab) reactivity in different populations, improve epidemic modeling and forecasting informing public health policy and intervention strategies [9, 10]. Table 1 summarizes the diverse applications of SARS-CoV-2 serological assays, as well as the still significant limitations in testing technologies and incomplete understanding of their performance characteristics and utility in different use cases. In the United States approximately 37 serological assays have received Food and Drug Administration (FDA) Emergency Use Authorizations (EUAs). These assays target different viral proteins (S1, S1/S2, RBD, NC) and have different configurations allowing detection of total immunoglobulin (Ig), IgG, IgM, or IgA [11]. Many factors influence test performance, including cross-reactivity with other coronaviruses [12], and assay configuration and platform (laboratory-based vs point-of-care (POC) lateral flow) and Ig target. Applications and Limitations of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody (Ab) Assays Abbreviations: ARV, antiretroviral; CCP, convalescent plasma; COVID-19, coronavirus disease 2019; FRs, first responders; HCWs, healthcare workers; H-Ig, hyperimmune immunoglobulin; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VISP, vaccine induced seropositivity. Applications and Limitations of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody (Ab) Assays Abbreviations: ARV, antiretroviral; CCP, convalescent plasma; COVID-19, coronavirus disease 2019; FRs, first responders; HCWs, healthcare workers; H-Ig, hyperimmune immunoglobulin; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VISP, vaccine induced seropositivity. Sensitive and specific antibody tests can and are critically needed to identify and survey population infections. Such surveys of serological incidence are powerful and effective tools for monitoring the development and progression of the epidemic and in determining the increase in herd immunity [13]. It is expected that individuals with strong antibody responses will be immune to reinfection, protecting both themselves from reinfection and reducing further viral spread by raising herd immunity. However, for many viruses, including other human coronaviruses that cause common colds, antibody responses can wane over time [14], leaving individuals susceptible to reinfection. Therefore, it is critical to understand immune persistence by following a cohort of individuals such as those volunteering to donate convalescent plasma (CCP) to characterize their antibody levels over time. There are many approaches to serosurveillance that involve testing of at-risk populations, such as healthcare workers and first responders, community recruitment strategies based on rapid POC testing or home collected dried blood spot (DBS) sampling, or testing residual clinical laboratory samples. Blood donor-based serosurveillance is increasingly recognized as a powerful and cost-effective strategy to monitor infectious diseases including evolving emerging infectious disease (EID) epidemics. Past studies have provided insights into how to execute and interpret blood donor serosurveillance studies for a large number of viruses for which routine donor screening is performed, including human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), human T-lymphotrophic virus (HTLV), and West Nile virus (WNV). During a large dengue virus type 4 (DENV-4) epidemic in Rio de Janeiro, Brazil, in 2012 we calculated the seroincidence of DENV in the blood donor population over the course of the outbreak to be 6.2–6.8% [15]. During the large 2013–2014 chikungunya virus (CHIKV) epidemic we calculated the seroincidence of CHIKV in the Puerto Rican blood donor population to be 23.5% [16]. The use of blood donor samples allows the sampling of asymptomatic and recovered cases of COVID-19 28 days following COVID-19 symptom resolution. The earliest blood donor-based serosurveillance studies were reported from Denmark and the Netherlands [17, 18]. The Danish study reported in this issue of Clinical Infectious Diseases, the first report of blood donor based serosurvey, employed rapid, low cost, and convenient POC testing of donor blood samples (adjusting for assay sensitivity and specificity), extrapolated the donor based results to the general Danish population, and derived infection to case and mortality ratios. Strengths of the study are its broad national population representativeness and use of the donor population to capitalize on the capacity to conduct ongoing serial cross-sectional analyses to track outbreak over time and correlate incidence with implementation and relaxation of pandemic mitigation measures. However, the study findings are limited by the use of a POC assay with poor sensitivity (82.58% [75.68–88.20]) and lack of confirmatory testing. This highlights the importance of selection and evaluation of appropriate sensitive and specific assays and supplemental assays to confirm SARS-CoV-2 seroreactivity in order to effectively perform large-scale donor serosurveys , which will become even more important as SARS-CoV-2 vaccines are introduced. In the United States, the REDS-IV-P program RESPONSE (REDS-IV-P Epidemiology, Surveillance, and Preparedness of the Novel SARS-CoV-2 Epidemic) initiated SARS-CoV-2 serological testing of residual donor serum in March 2020. The study is testing 1000 individual blood donations collected monthly from each of 6 metropolitan regions, including the San Francisco Bay Area, Seattle, New York City, Los Angeles, Boston, and Minneapolis (https://redsivp.com/covid-19/). Routinely collected donor demographics including age, sex, race-ethnicity, and zip code of residence are linked to coded samples that are tested using a robust algorithm that includes screening with an S1 total Ig assay, with reactive samples confirmed with a NC total Ig assay and a pseudovirus-based neutralization assay. The US Centers for Disease Control and Prevention (CDC) recently funded a program to expand this study from 6 sites for 6 months to a total of over 60 European Centre for Disease Prevention and Control US regions from all 50 states and Puerto Rico with monthly collections of 2000 samples per site for 12 months, plus final testing at 18 months (https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/geographic-seroprevalence-surveys.html). This will allow a detailed analysis of the increasing penetrance of infection by the virus into communities. Data will be compiled from all regions, collated, and linked to demographic data from the collection organizations. To provide estimates of infection incidence based on Ab reactivity at the general population level by city and state, group-specific donor estimates will be computed, then adjusted to the population group distributions using poststratification- or calibration-type weighting [19]. Overall and subgroup-specific estimates will be calculated and reported with uncertainty statements including computation and reporting of standard errors and/or confidence intervals. We will also partner with academic and CDC colleagues leading community SARS-CoV-2 serostudies to correlate our blood donor-derived seroincidence data with data from those studies in order to develop algorithms to correct for initial biases. We will calculate changes in overall, geographic region, age- sex- and race-ethnicity-specific seroincidence of SARS-CoV-2 in donor populations and extrapolated general populations by month over the course of the study and relate those results to clinical cases and deaths and community serosurvey data with aggregate and stratified data posted by CDC in near real time. Persistence of humoral responses to SARS-CoV-2 that will determine lasting individual and herd immunity must also be accounted for to accurately estimate evolving serological incidence in cross-sectional serosurveillance studies. We have conducted numerous longitudinal follow-up studies of donors following acute infections with transfusion-transmitted viruses (eg, HIV, HBV, HCV) and emerging infectious diseases (eg, WNV, CHIKV, DENV, ZIKV, Trypanosoma cruzi, Babesia microti). For acute arboviral infections these studies have characterized both the dynamics of early Ab seroconversion and the waning of Abs. We have worked closely with CDC to account for the waning of WNV IgM, ZIKV IgG, and neutralizing Abs to apply linear regression modeling to derive adjusted cumulative incidence estimates from cross-sectional serosurvey data for viruses with transient infections followed by waning of serological responses [20–22]. The important consequence of waning of SARS-CoV-2 Ab responses for serosurveys, such as the serial cross-sectional serosurveys of blood donors, is that declining Ab responses in the months to years following infection would result in underestimation of cumulative incidence if not accounted for in the analysis. In conclusion, serial serosurveillance studies of SARS-CoV-2 using blood donor populations, which are now being implemented in many countries, provide a powerful adjunct to other approaches that are prospectively monitoring outbreak activity. Although serosurveillance data from asymptomatic blood donors trail viral transmission and case reporting by approximately 1 month, if these studies are well designed and executed and carefully analyzed and interpreted, they provide longitudinal and systematic data to inform our understanding of the epidemiology and effectiveness of responses to this unprecedented pandemic. Potential conflicts of interest. The authors: No reported conflicts of interest. Both authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Busch et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: